N. Freemantle, M. Calvert, J. Wood, J. Eastaugh, and C. Griffin. JAMA : the journal of the American Medical Association, 289 (19):
2554-9(May 2003)3350<m:linebreak></m:linebreak>Comparacions múltiples; Composite endpoints.
F. Ambrogi, E. Biganzoli, and P. Boracchi. Statistics in medicine, 27 (30):
6407-25(December 2008)4677<m:linebreak></m:linebreak>JID: 8215016; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
S. Messinger, and S. Murray. Statistics in medicine, 24 (2):
301-18(January 2005)4149<m:linebreak></m:linebreak>PUBM: Print; JID: 8215016; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
S. Lagakos. The New England journal of medicine, 355 (2):
113-7(July 2006)4860<m:linebreak></m:linebreak>LR: 20071115; JID: 0255562; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CON: N Engl J Med. 2005 Mar 17;352(11):1092-102. PMID: 15713943; 2006/06/26 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
J. Delaney, S. Daskalopoulou, and S. Suissa. Pharmacoepidemiology and drug safety, 18 (1):
1-6(January 2009)5076<m:linebreak></m:linebreak>JID: 9208369; 0 (Adrenergic beta-Antagonists); ppublish;<m:linebreak></m:linebreak>Anàlisi de dades; Marginal structural models; Exemple.
L. Mell, and J. Jeong. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (28):
4297-9(October 2010)Comparacions múltiples.